Pre-IND, End-Of-Phase II Meetings Can Decrease Development Time, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency data indicate taking advantage of the early meetings with FDA officials can dramatically decrease mean clinical development times, especially for rare disease applications.
You may also be interested in...
US FDA Begins Building Pharma Industry Activity Prediction Tool
Algorithms are intended to help predict incoming workload, which will be used to help set user fees.
Industry Wants A Breakthrough Therapy, Even Without All The Standards
A few requests have gone to FDA for candidates to be named breakthrough therapies and gain access to shorter development programs, but the agency has not established all the program requirements yet.
FDA To Provide Expedited Approval Desktop Reference
Comprehensive guidance document is expected to describe FDASIA changes and clarify terms that have become confusing as more pathways emerge to speed drug approvals.